Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04562870 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04562870 · ClinicalTrials.gov record · last posted 2026-07-02

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

StatusActive, Not Recruiting
PhasePhase 2
Started2021-03-17
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.

Amendment record 27 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 27 times since 2020-09-23; most recent amendment 2026-06-30. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-05-25
Status change Recruiting→Active, Not Recruitingv18
2021-05-05
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT04562870
Lead Sponsor Karyopharm Therapeutics Inc
Conditions Myelofibrosis
Enrollment 112 participants
Start Date 2021-03-17
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-02